We describe a rapid target enrichment method for next-generation sequencing, termed
anchored multiplex PCR (AMP), that is compatible with low nucleic acid input from formalin …

Invasive mucinous adenocarcinoma (IMA) is a unique histologic subtype of lung
adenocarcinoma. Recent studies document distinctive genetic alterations (eg, NRG1 …

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer
Harboring ROS1 Rearrangement Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL …

Purpose To investigate the frequency and the prognostic role of fibroblast growth factor
receptor 1 (FGFR1) amplification in patients with surgically resected squamous cell …

Introduction: Invasive mucinous adenocarcinoma is a unique histologic subtype of lung
cancer, and our knowledge of its genetic and clinical characteristics is rapidly evolving …

BACKGROUND: The objectives of this study were to determine the proportions of major
oncogenic alterations and to examine survival in genotype‐specific subsets of never …

Targeted therapies guided by molecular diagnostics have become a standard treatment of
lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma …

Introduction PD-L1 expression is a predictive biomarker for response to anti-programmed
cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors …

Next-generation sequencing (NGS) has recently emerged as an essential component of
personalized cancer medicine due to its high throughput and low per-base cost. However …

Approximately 7% of non–small cell lung carcinomas (NSCLCs) harbor oncogenic fusions
involving ALK, ROS1, and RET. Although tumors harboring ALK fusions are highly sensitive …